Ignite Creation Date:
2024-05-05 @ 4:40 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00285688
Status:
COMPLETED
Last Update Posted:
2020-10-19
First Post:
2006-02-01
Brief Title:
Antibiotic Resistant Helicobacter Pylori in Rajavithi Hospital
Sponsor:
Rajavithi Hospital
Organization:
Rajavithi Hospital
Study Overview
Official Title:
Antibiotic Resistance Helicobacter Pylori and Clarithromycin Resistance Mutation in Helicobacter Pylori in Rajavithi Hospital
Status:
COMPLETED
Status Verified Date:
2020-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Peptic ulcer disease is the most common gastrointestinal disease Antibiotic resistant Helicobacter pylori is a major problem worldwide The gold standard for Helicobacter pylori eradication is composed of Proton-pump inhibitorRanitidine bismuth citrate Amoxycillin Metronidazole Clarithromycin In Thailand clarithromycin resistant strains increased and led to treatment failure Data on file at Rajavithi Hospital showed that metronidazole resistant H pylori was about 50 and Clarithromycin resistant strains accounted for 8 This molecular genetic study will be performed in patients presenting with dyspepsia who had an indication for gastroscopic examination to explore the incidence of antibiotic resistant Helicobacter pylori in Rajavithi Hospital Thailand
Detailed Description:
Genetic and Biomolecular factors determining clarithromycin resistance will be characterized
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None